Press releases

2020  |  2019  |  2018  |  All
March 30, 2020
Compass Therapeutics Announces Publication of Data Demonstrating the Preclinical Efficacy and Safety of CTX-471, a Unique Fully Human Agonist of CD137
February 28, 2020
Compass Therapeutics to Present at the 40th Cowen Health Care Conference
January 6, 2020
Compass Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

Presentations and publications

View all
November 12, 2019 | SITC 2019
CTX-8371, a Novel Bispecific Targeting both PD-1 and PD-L1, is more Potent than Combination anti-PD-1 and PD-L1 Therapy and Provides Enhanced Protection from Tumors in vivo
November 12, 2019 | SITC 2019
A novel class of Innate Cell Engagers targeting NKp30
April 10, 2019 | Keystone Symposia Conference: “D2: Antibodies as Drugs: New Horizons in the Therapeutic Use of Engineered Antibodies”
Novel class of NK engagers targeting NKp30 selected from unbiased screen of common light chain based bispecific antibodies

In the news

View all
December 11, 2019
Nature Reviews Drug Discovery: Immune agonist antibodies face critical test
December 4, 2019
BioWorld -Two’s companies: Crowd in bispecifics still growing as methodology sorted
October 2, 2018
FierceBiotech’s 2018 Fierce 15

Events

AACR Annual Meeting
April 24 – 29
San Diego, California
16th Annual PEGS Boston
May 4 – 8
Boston, Massachusetts
ASCO Annual Meeting
May 29 – June 2
Chicago, Illinois